Posted by Michael Wonder on 01 Feb 2023
Trastuzumab deruxtecan for treating HER2 positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments
1 February 2023 - Trastuzumab deruxtecan is recommended with managed access as an option for the treatment of adults with HER2 positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments.
It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.
